Physician profile
Puneet Kumar
NPI 1871594044
$7,267.33
in general payments reported to CMS, 2019-2025
26 companies · $1,597 in 2025
The $1,597 reported for 2025 was more than what 92% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $666 · 2020: $216 · 2021: $891 · 2022: $1,257 · 2023: $1,390 · 2024: $1,251 · 2025: $1,597.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,219 · Education: $17.86.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,219.49 |
| Education | $17.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,623.54 | 2019-2025 | |
| Janssen Biotech, INC. | $809.58 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $715.09 | 2019-2025 | Entyvio, Eohilia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.30 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Pfizer INC. | $266.11 | 2019-2025 | |
| Ardelyx, INC. | $253.83 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $197.68 | 2022-2025 | |
| Novo Nordisk INC | $189.61 | 2023-2025 | Wegovy |
| Qol Medical, LLC | $162.58 | 2019-2025 | Sucraid, Sucraid |
| Medtronic, INC. | $91.67 | 2021-2024 | Pillcam, Gi Genius |
| Lilly USA, LLC | $86.40 | 2023-2025 | Omvoh |
| Merck Sharp & Dohme LLC | $79.30 | 2021-2024 | Dificid |
| Celltrion USA INC. | $76.16 | 2024-2025 | Zymfentra, Vegzelma |
| Amgen INC. | $49.91 | 2022-2023 | Avsola, Amjevita |
| Ferring Pharmaceuticals INC. | $48.18 | 2019-2023 | Rebyota |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $45.43 | 2019-2021 | |
| Ipsen Biopharmaceuticals, INC | $35.58 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $33.72 | 2024 | |
| Boston Scientific Corporation | $33.07 | 2023-2024 | |
| Pharmacosmos Therapeutics INC. | $26.32 | 2023 | Monoferric |
| Daiichi Sankyo INC. | $24.74 | 2024 | Injectafer |
| Madrigal Pharmaceuticals | $23.30 | 2024 | Resmetirom |
| Intercept Pharmaceuticals, INC. | $20.52 | 2023 | Ocaliva |
| Phathom Pharmaceuticals, INC. | $17.35 | 2025 | Voquezna |
| Alnylam Pharmaceuticals INC. | $13.87 | 2021 | |
| Mauna Kea Technologies, INC. | $9.49 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Puneet Kumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.